These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29076032)

  • 1. Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.
    Balán IC; Giguere R; Brown W; Carballo-Diéguez A; Horn S; Hendrix CW; Marzinke MA; Ayudhya RPKN; Patterson K; Piper JM; McGowan I; Lama JR; Cranston RD;
    AIDS Behav; 2018 Mar; 22(3):986-995. PubMed ID: 29076032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
    Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
    PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
    Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
    AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.
    van der Straten A; Brown ER; Marrazzo JM; Chirenje MZ; Liu K; Gomez K; Marzinke MA; Piper JM; Hendrix CW;
    J Int AIDS Soc; 2016; 19(1):20642. PubMed ID: 26850270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disclosure of pharmacokinetic drug results to understand nonadherence.
    van der Straten A; Montgomery ET; Musara P; Etima J; Naidoo S; Laborde N; Hartmann M; Levy L; Bennie T; Cheng H; Piper J; Grossman CI; Marrazzo J; Mensch B;
    AIDS; 2015 Oct; 29(16):2161-71. PubMed ID: 26544581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
    Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
    AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.
    Wang X; Nutland W; Brady M; Green I; Boffito M; McClure M
    Int J STD AIDS; 2019 Jul; 30(8):765-768. PubMed ID: 31072205
    [No Abstract]   [Full Text] [Related]  

  • 10. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
    Mensch BS; Brown ER; Liu K; Marrazzo J; Chirenje ZM; Gomez K; Piper J; Patterson K; van der Straten A
    AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.
    Musinguzi N; Muwonge T; Thomas K; Baeten JM; Bangsberg DR; Haberer JE
    AIDS Behav; 2016 Nov; 20(11):2639-2643. PubMed ID: 26781865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW; Towns JM; Mcnulty A; Pierce AB; Foster R; Richardson R; Carr A
    AIDS; 2017 Jun; 31(9):1291-1295. PubMed ID: 28301425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills.
    Chai PR; Pereira LM; Jambaulikar GD; Carrico AW; O'Cleirigh C; Mayer KH; Boyer EW
    AIDS Res Hum Retroviruses; 2019 Apr; 35(4):361-363. PubMed ID: 30693811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
    Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
    AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.